Walleye Capital
TGTX icon

Walleye Capital’s TG Therapeutics TGTX Stock Holding History

Walleye Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5M Buy
190,302
+188,284
+9,330% +$7.71M 0.04% 459
2026
Q1 		$67K Sell
2,018
-58,548
-97% -$1.74M ﹤0.01% 3813
2025
Q4 		$1.81M Buy
60,566
+47,029
+347% +$1.54M 0.01% 1957
2025
Q3 		$489K Buy
13,537
+12,728
+1,573% +$419K ﹤0.01% 2629
2025
Q2 		$29.1K Sell
809
-8,252
-91% -$307K ﹤0.01% 4177
2025
Q1 		$357K Sell
9,061
-14,808
-62% -$498K ﹤0.01% 2822
2024
Q4 		$718K Buy
23,869
+18,623
+355% +$534K ﹤0.01% 2679
2024
Q3 		$123K Buy
+5,246
New +$115K ﹤0.01% 4304
2024
Q2 		– Sell
-11,017
Closed -$176K – 6007
2024
Q1 		$168K Buy
11,017
+1,253
+13% +$20K ﹤0.01% 4086
2023
Q4 		$167K Sell
9,764
-79,409
-89% -$923K ﹤0.01% 3779
2023
Q3 		$745K Buy
+89,173
New +$1.24M ﹤0.01% 2487
2022
Q3 		– Sell
-198,233
Closed -$842K – 3543
2022
Q2 		$842K Buy
+198,233
New +$1.24M 0.02% 735
2020
Q2 		– Sell
-16,540
Closed -$162K – 961
2020
Q1 		$162K Sell
16,540
-13,860
-46% -$175K 0.04% 490
2019
Q4 		$338K Buy
+30,400
New +$231K 0.02% 864

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Walleye Capital's TGTX Position: Q2 2026 in Review

Walleye Capital increased its TG Therapeutics (TGTX) stake by 9,330% in Q2 2026, buying an estimated $7.71M and bringing the position to 190,302 shares worth $10.5M. The position accounts for 0.04% of the portfolio, ranked #459.

Walleye Capital first reported a position in TGTX in Q4 2019 and has held it in 14 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Walleye Capital held 190,302 shares of TG Therapeutics worth $10.5M as of Q2 2026.
  • Walleye Capital bought 188,284 TG Therapeutics shares in Q2 2026, an estimated $7.71M.
  • TG Therapeutics made up 0.04% of Walleye Capital's portfolio in Q2 2026, its #459 holding.
  • Walleye Capital first reported a position in TG Therapeutics in Q4 2019 and has held it in 14 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.